Race Oncology Limited announced that it has appointed Professor Jianjun Chen of the City of Hope Hospital, Los Angeles, to its Scientific Advisory Board (SAB). Prof Chen and his team recently identified Bisantrene as a potent inhibitor of the Fat Mass and Obesity associated protein (FTO) published in the journal Cancer Cell in July 2020. Overexpression of FTO has been shown to have central role in the proliferation and spread of a wide range of cancers via its regulation of the m6A RNA methylation pathway. Prof Jianjun Chen is the Simms/Mann Family Foundation Chair in Systems Biology at the Beckman Research Institute City of Hope Hospital. His laboratory of 22 scientists focuses on both basic and translational research associated with RNA/DNA epigenetics, especially RNA methylation/demethylation related to the N6 methyladenosine (m6A) machinery and has identified several small-molecule compound inhibitors, including Bisantrene, with therapeutic potential in this area.